Pharmaceutical Technology, Dec 2, 2007 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Dec 2, 2007
Online Exclusive
Required Reading for Regulatory-Affairs Personnel
By Russell E. Madsen
How do you answer an inspector's questions? How do you validate analytical methods? One book has answers for compliance professionals.
Special Report
Pharmaceutical Technology's Annual Employment Survey
By Maribel Rios
Nearly 1300 pharmaceutical employees provide insights into the issues most relevant to their jobs and the state of the industry workforce today.
30 Years Hence: It Won't Be Your Parents' Pharmaceutical Industry
By Michelle Hoffman
"May you live in interesting times," goes the allegedly ancient Chinese curse. Well, these have been "interesting times" indeed for those working in the pharmaceutical industry.
What's Next in: Strategy and Regulation
By Maribel Rios , Jill Wechsler
There are at least two major factors that will shape the manufacturing industry as a whole. Daniel Ruppar, Industry Manager (North America) for the Pharmaceuticals and Biotechnology Division of Frost & Sullivan predicts that, due to continued globalization, we can expect to see "growth centers for the industry move to emerging market sectors."
What's Next In: Outsourcing
By Jim Miller
Contract service providers exist to help clients meet their strategic and financial business objectives. So any prognostication on what the pharmaceutical outsourcing industry will look like in 30 years is really a forecast of the nature and speed of changes in pharmaceutical technologies and business models.
What's Next In: Solid-Dosage Formulation
By Robin Bogner , Stuart C. Porter , Albert W. Brzeczko
Individualized dosing for specific patient needs has been the goal of medical and pharmacotherapy specialists since they first envisioned pharmacogenetic evaluation. With the measurement of individual levels of metabolism, the optimum dose can be calculated for each individual patient.
What's Next In: Ingredients
By Richard L. Pederson, PhD
Catalysis plays a critical role in the synthesis of active pharmaceutical ingredients (APIs). It provides a way to improve yield, achieve desired stereoselectivity, improve reaction conditions, and synthesize increasingly complex APIs. Recent advances in catalyzed-olefin metathesis reveal its value and promise in the pharmaceutical industry.
What's Next In: Drug Delivery
By Mansoor M. Amiji
Nanotechnology offers an unprecedented opportunity in the rational delivery of drugs and vaccines (1, 2–4).
What's Next In: Packaging
By Hallie Forcinio
Although the highly regulated pharmaceutical industry tends to be more like the tortoise than the hare when it comes to adopting new ideas, pharmaceutical packaging will be dramatically different 30 years from now in 2037.
What's Next In: Analytical Testing
By Maribel Rios
Industry and regulatory organizations agree that the current focus on product quality will play a major role in shaping pharmaceutical development in the future. Key to this assessment of quality are the methods and technologies in pharmaceutical analytical testing.
What's Next In: Information Technology
By Herschel Kenney , Milind Joshi
I foresee dramatic future changes in five distinct areas of the pharmaceutical industry: Research, Regulatory Approval, Production, Sales & Marketing, and IT Infrastructure.
Peer-Reviewed Research
Preparation and Characterization of Meloxicam–Myrj-52 Granules Obtained by Melt Granulation
By Pramodkumar Sharma , Praveen Chaudhari , Hiren Bhagat , Nishant Varia
Various manufacturing techniques can improve a drug's solubility, thus increasing its bioavailability. The authors examined whether melt granulation can enhance drug solubility using meloxicam as the drug substance and myrj-52 as the binder.
The Disintegration and Dissolution of Nabumetone Dispersible Tablets
By H. N. Shivakumar , B.G. Desai , S. Narasimha Murthy , Ashish Sharma
The authors analyzed the effects of complexation as well as the levels of ammonium bicarbonate and crospovidone on tablet wetting time (WT), disintegration time (DT), and percent dissolution efficiency at 60 min (%DE60).
CMOs Expand Biologics Manufacturing
By Patricia Van Arnum
A surge in capacity in contract microbial and mammalian cell-culture is underway to meet rising production needs for biopharmaceuticals.
Washington Report
Generic Drugs for Everyone
By Jill Wechsler
To keep up with applications, FDA promotes new testing and administrative methods.
Pipeline Peril
By Jim Miller
The dynamics of the R&D pipeline could undercut recent CRO and CMO successes.
Why We Do What We Do
By Control, a senior compliance officer
The "why" things are done in this industry is just as important as the "what"and "how."
Pharma Predictions
In honor of Pharmaceutical Technology's 30th anniversary, the editors conducted a survey of 320 readers last spring to discuss industry advances and future directions. Here are some of your foward-looking responses.
From The Editor
Here's to Innovation
By Michelle Hoffman
Drug makers, drug inspectors, and drug consumers need to demand that new drugs be effective.
This Time Around
Go Green This New Year
By Angie Drakulich
As we get ready to head into the new year, chief executive and financial officers may be making their wish lists for 2008. Grow revenue. Increase pipeline. Establish new facility abroad. Acquire small-sized generics company. And so forth. But why not add something "green" to the list?Why not consider ways to help the environment while aiming for success?
In the Field
Congress Focuses on FDA Inspections of Foreign Drug Facilities; Medical Students Oppose Big Pharma's Influence on Campus; FDA Revises Postmarketing Reporting Requirements
In the Spotlight
In the Spotlight
Centrifuge processes many materials; New features for quality-management software; Unit simplifies powder discharge
Pharma Capsules
Pharma Capsules


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here